Immediate Impact
14 standout
Citing Papers
The IL-17 family in diseases: from bench to bedside
2023 Standout
Challenges and Future Trends in the Treatment of Psoriasis
2023 Standout
Works of I Clement' being referenced
Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate‐to‐severe plaque psoriasis (UNCOVER ‐A)
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|
| I Clement' | 2 | 4 | 29 | 16 | 9 | 2 | 36 | |
| S. Mburu | 3 | 3 | 43 | 16 | 5 | 3 | 46 | |
| M T Camps | 16 | 8 | 22 | 2 | 33 | |||
| Antonio Lopes-Vaz | 2 | 17 | 4 | 5 | 2 | 29 | ||
| Tamara Casper | 2 | 42 | 8 | 3 | 2 | 47 | ||
| A. E. Barclay | 4 | 17 | 12 | 2 | 4 | 45 | ||
| S. Leighton | 3 | 17 | 65 | 34 | 10 | 5 | 164 | |
| Guillaume Bayer | 2 | 2 | 9 | 4 | 12 | 3 | 30 | |
| Cindy Zhang | 1 | 5 | 4 | 5 | 7 | 2 | 39 | |
| Mayret Castillo | 4 | 10 | 14 | 10 | 6 | 5 | 178 | |
| Zhenhua Gan | 4 | 13 | 10 | 3 | 3 | 170 |
All Works
Login with ORCID to disown or claim papers
Loading papers...